SKF83959, an Agonist of Phosphatidylinositol-Linked D1-Like Receptors, Promotes ERK1/2 Activation and Cell Migration in Cultured Rat Astrocytes

Chao Huang1, Jingjing Wu2, Rujia Liao1, Wei Zhang1*

1 Department of Pharmacology, School of Medicine, Nantong University, Nantong, Jiangsu, People's Republic of China, 2 Department of Internal Medicine, Suzhou Kowloon Hospital, Suzhou, Jiangsu, People's Republic of China

Abstract

Extracellular signal-regulated kinase 1/2 (ERK1/2) is a member of the mitogen-activated protein kinase family. It can mediate cell migration. Classical dopamine receptor-mediated ERK1/2 phosphorylation is widely studied in neurons. Here, we report that ERK1/2 phosphorylation is also modulated by putative phosphatidylinositol-linked D1-like receptors in cultured rat astrocytes. 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959), an agonist of the putative phosphatidylinositol-linked D1-like receptors, was found to enhance ERK1/2 phosphorylation, which then promoted the migration of cultured astrocytes. The SKF83959-induced ERK1/2 phosphorylation was found to be Ca2+-independent based on the following observations: i. chelating intracellular Ca2+ did not inhibit ERK1/2 phosphorylation and astrocyte migration; ii. blockage of the release of intracellular Ca2+ from the endoplasmic reticulum by an inhibitor of inositol 1,4,5-trisphosphate (IP3) receptor did not attenuate ERK1/2 phosphorylation. However, inhibition of phospholipase C (PLC), the upstream molecule of internal Ca2+ release, disabled SKF83959’s ability to elevate the level of ERK1/2 phosphorylation. Both non-selective protein kinase C (PKC) inhibitor and PKCδ selective inhibitor prevented ERK1/2 phosphorylation increase and astrocyte migration in any medium, but PKCs inhibitor did not. This suggests that Ca2+-independent and diacylglycerol-dependent PKCδ acts downstream of putative phosphatidylinositol-linked D1-like receptor activation and mediates SKF83959-induced elevation of ERK1/2 phosphorylation in order to modulate astrocyte migration. In conclusion, our results demonstrate that SKF83959-induced increases in ERK1/2 phosphorylation and astrocyte migration are dependent on PLC-PKCδ signals. This might help us to further understand the functions of the putative phosphatidylinositol-linked D1-like receptors in the nervous system.

Citation: Huang C, Wu J, Liao R, Zhang W (2012) SKF83959, an Agonist of Phosphatidylinositol-Linked D1-Like Receptors, Promotes ERK1/2 Activation and Cell Migration in Cultured Rat Astrocytes. PLoS ONE 7(11): e49954. doi:10.1371/journal.pone.0049954

Received June 11, 2012; Accepted October 15, 2012; Published November 19, 2012

Copyright: © 2012 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Natural Science Foundation of China to Dr. Chao Huang (No. 81102428).

Competing Interests: The authors have declared that no competing interests exist.
* E-mail: asicamp@yahoo.com.cn

Introduction

Dopamine (DA) can regulate emotion, cognition, locomotion, and endocrine function [1,2]. The roles of DA are mediated by distinct DA receptors (D1–D5). Among these receptors, classical cyclase-coupled D1 receptors are linked to Gs protein that can stimulate cyclic AMP (cAMP) formation [3]. However, non-cyclase-coupled D1-like receptors were connected to Gq protein to promote phospholipase C (PLC) activation and the subsequent hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) [4]. Non-cyclase-coupled D1-like receptor was named phosphatidylinositol (PI)-linked D1-like receptor because of its ability to activate Gq/PLC/inositol 1,4,5-trisphosphate (IP3) signals [5]. SKF83959, an agonist of the putative PI-linked D1-like receptor can be used to identify new roles of atypical DA receptors in the nervous system [6,7,8]. For example, one study showed that stimulation of striatal neurons by SKF83959 induces an inhibition of high-voltage-activated (HVA) Ca2+ currents, which was proven to be dependent on PLC/IP3/Ca2+/calcineurin signals [9]. SKF83959 can also alleviate dyskinesia, a symptom of Parkinson’s disease, in in vivo models [7]. In brain slices, SKF83959 activates the cAMP-response element binding protein (CREB) and dopamine 3’5’-monophosphate-regulated phospho-protein 32 (DARPP-32) via PLC/IP3/Ca2+/calcium-calmodulin-dependent protein kinase II (CaMKII) and PLC/IP3/Ca2+/cyclin-dependent kinase 5 (CDK5) signals, respectively [10].

Astrocytes, regarded as supporting structures in the nervous system, are generally thought to act as a syncytium of interconnected cells, rather than as individual bodies [11]. In most cases, the functions of astrocytes are mediated primarily by their membrane transporters and receptors such as the glutamate transporters and classical DA receptors [12,13,14]. Putative PI-linked D1-like receptors have also been found to modulate astrocyte function. For instance, activation of the putative PI-linked D1-like receptors by SKF83959 up-regulates astrocyte-derived fibroblast growth factor-2 (FGF-2) expression via PLC/IP3/Ca2+/CaMKII signals, which potentially protects dopaminergic neurons from 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity [6]. Regardless of whether the targets of SKF83959 are astrocytes or neurons, the known effects of SKF83959 correlate with the increase in intracellular Ca2+. Data from our previous study also showed a release of internal
Ca²⁺ from endoplasmic reticulum (ER) in cultured astrocytes after SKF83959 treatment [15]. Previous studies mainly evaluated changes in the activation of Ca²⁺-related kinases such as CaMKII in response to SKF83959 application. However, due to the complexity of DA signal transduction pathways, we focused on whether other signal molecules could mediate SKF83959’s effects on astrocytes.

Extracellular signal-regulated kinase 1/2 (ERK1/2) may be involved in this process. ERK1/2 is a member of the mitogen-activated protein kinase family, whose activation in response to stimuli is involved in cell migration and proliferation [16,17]. For example, activation of the ERK1/2 signals promotes transforming growth factor-β1-induced astrocyte migration [18]. Chronic ERK1/2 activation in neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease can be mediated by the classical DA receptors [19–21]. However, it is still unclear whether the putative PI-linked D₁-like receptors can mediate the classical DA receptors [19–21]. However, it is still unclear whether the putative PI-linked D₁-like receptors can mediate ERK1/2 activation in cultured astrocytes. Our present study demonstrates that SKF83959 promotes ERK1/2 phosphorylation by augmenting PLC-protein kinase C (PKC) signaling in cultured rat astrocytes. Both ERK1/2 and PKCδ inhibition functionally inhibit SKF83959-induced astrocyte migration. Our observations regarding SKF83959-induced ERK1/2 activation in astrocytes might provide new perspectives on the roles of the putative PI-linked D₁-like receptors in the nervous system.

Materials and Methods

Chemicals and Reagents

Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12) was obtained from Gibco Invitrogen Corporation (Carlsbad, CA, USA). Heat-inactivated fetal bovine serum was purchased from Hyclone (Logan, UT, USA). Poly-L-lysine, PD98059, BAPTA-AM, GF109203X, G06976, prazosin, hydroxyurea, rottlerin, and Hoechst 33258 were purchased from Sigma (Saint Louis, MO, USA). SKF83959, 2-APB, SCH23390, and U-73122 were purchased from Tocris Bioscience (Ellisville, MO, USA). Antibodies against phospho-ERK1/2 and total-ERK1/2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Acsam (Cambridge, MA, USA), respectively. Antibodies against total-CaMKII, phospho-CaMKII (Thr286), and β-actin were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibody against GFAP was the product of NeoMarkers (Fremont, CA, USA). Both goat anti-mouse IgG polyclonal secondary antibody for Western blot and rabbit anti-mouse tetramethylrhodamine isothiocyanate-conjugated secondary antibody for immunofluorescence were purchased from Thermo Scientific (Rockford, IL, USA). Other related agents were purchased from commercial suppliers. All drugs were prepared as stock solutions, and stock solutions were stored at −20°C. The final concentration of DMSO was <0.05%. No detectable effects of DMSO were found in our experiments.

Cell Preparation

The use of rats was approved by the University Animal Ethics Committee of Nantong University (Permit Number: 2110836). Rat primary cultured cells were prepared as described previously with some modifications [22]. Briefly, newborn (day 0–1) rats were decapitated, and their cortex were removed and digested with 0.125% trypsin for 15–20 min at 37°C. Followed by trituration and centrifugation at 118 g for 5 min, cells were re-suspended and plated on poly-L-lysine (1 mg/mL)-coated culture flasks. The single-cell suspension was then cultured in DMEM/F12 supplement with 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin (100 U/mL). For astrocytes, the medium was changed to fresh DMEM/F12 medium after 24 h and replaced every 3 days. After 12 days, mixed cells were shaken gently overnight (18 h), and then the supernatant was removed. Next the remaining cells were digested with 0.125% trypsin for 5 min and plated on new poly-L-lysine-coated culture flasks. All cultures were maintained in a 37°C incubator containing 95% air and 5% CO₂. Immunofluorescence with glial fibrillary acidic protein (GFAP) antibody was used to identify the astrocyte. The purity of the astrocyte culture exceeded 90%.

Immunofluorescence in Rat Astrocytes

Cultured astrocytes were fixed with 4% paraformaldehyde in 0.01 M phosphate-buffered saline (PBS, pH 7.4) for 30 min, and then rinsed three times with PBS for 10 min each. Immunofluorescence study was performed to determine the expression of GFAP in astrocytes. First, cells were permeabilized with PBS containing 0.3% (v/v) Triton X-100 for 30 min and blocked with 1% bovine serum albumin in PBS for 1 h, and then incubated with 1:100 anti-GFAP antibody in PBS containing 0.3% Triton X-100, 1% bovine serum albumin, and 2% goat serum overnight at 4°C. After rinsing in PBS three times, the cells were incubated with rabbit anti-mouse tetramethylrhodamine isothiocyanate-conjugated secondary antibody (1:50) for 1 h at room temperature. Then, the cells were incubated with Hoechst 33258 (20 min) for nucleus staining. Eventually, the samples were mounted on glass slides with 30% glycerin and imaged using a confocal laser scanning microscope (FV500; Olympus). The purity of astrocyte culture was calculated by the ratio of the GFAP and Hoechst 33258-stained cell numbers.

Western Blot

To extract the total proteins, purified rat astrocytes were lysed on ice for 30 min in lyses buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 100 mM NaCl, 20 mM NaF, 3 mM Na₃VO₄, 1 mM PMSF, with 1% (v/v) Nonidet P-40, and protease inhibitor cocktail). The lysates were recovered by centrifugation at 12000 g for 15 min. After denaturation, the proteins (30 μg) were separated on 10% SDS/PAGE gels and then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). After blocking with 5% nonfat dried milk powder/Tris-buffered saline Tween-20 (TBST) for 1 h, membranes were probed with 1:500 primary antibodies against total ERK1/2 (42/44 kD) and phospho-ERK1/2 (42/44 kD) or 1:5000 primary antibody against β-actin (43 kD) overnight at 4°C. Primary antibodies were then removed by washing the membranes 3 times in TBST, and incubated for further 1 h at room temperature with goat anti-mouse IgG polyclonal secondary antibody (1:3000-1:5000) that are conjugated with polymers of horseradish peroxidase. Following 3 times of washing in TBST, immunoblots were developed on films using the enhanced chemiluminescence (ECL) technique (Pierce, Rockford, USA). The band density was quantified using Image J software. All assays were performed at least three times.

Cell Migration Assay

Astrocytes plated on poly-L-lysine (1 mg/mL)-coated coverslips were cultured to confluence in 35 mm dishes. The monolayer cells were scratched manually with a pipette tip to create extended and definite scratches in the center of the coverslips with a bright and clear field, and then the detached cells were immediately removed by washing the cells with fresh medium. Growth medium with or without SKF83959 was added to each dish after pretreatment with inhibitors for 30 min. Hydroxyurea, an inhibitor of DNA synthesis...
was added to prevent the proliferation of astrocytes during the period of observation. Numbers of migratory astrocytes from the scratched boundary were counted from the resulting four phase images for each point with a digital camera and a light microscope (Olympus, Japan) and then averaged for each experimental condition. The data presented were generated from three separate assays.

Statistical Analysis

Data were expressed as mean ± SE. Comparisons for dose- and time-dependent data were made using a two-tailed Student’ paired t test and corrected by Bonferroni. Comparisons for other data were made using unpaired t test. Differences were considered statistically significant at P < 0.05 or P < 0.01.

Results

SKF83959 Enhances ERK1/2 Phosphorylation and Cell Migration in Cultured Rat Astrocytes

Dopamine receptors have been reported to mediate ERK1/2 phosphorylation and activation in the nervous system. To evaluate the effects of the agonist of the putative PI-linked D1-like receptors SKF83959 on astrocytes, we first confirmed the purity of cultured cortical astrocytes. As shown in Fig. 1A, cell nuclei were stained

Figure 1. Effects of SKF83959 on ERK1/2 phosphorylation and cell migration in cultured rat astrocytes. (A) Cultured cortical astrocytes were identified using GFAP immunofluorescence and Hoechst 33258 staining. Bar: 20 μm. (B) Cultured astrocytes were incubated with 30 μM SKF83959 for 2 to 60 min. (C) A time-course analysis of ERK1/2 phosphorylation levels upon SKF83959 incubation from three independent experiments (Mean ± S.E., n = 3, **P < 0.01 or *P < 0.05, vs. control). (D) Cultured cortical astrocytes were treated with SKF83959 at different concentrations (1, 10, 30, 50, and 100 μM) for 10 min. (E) Quantification of ERK1/2 phosphorylation level in astrocytes upon incubation with different concentrations of SKF83959 in three independent experiments (Mean ± S.E., n = 3, **P < 0.01 or *P < 0.05, vs. control). (F) Effects of PD98059 (20 μM, 30 min), a specific inhibitor of MAP kinase, in SKF83959 (30 μM, 24 h)-induced migration of astrocytes. Bar: 5 μm. (G) Quantification of SKF83959-induced migration of astrocytes upon pretreatment with PD98059 (Mean ± S.E., n = 3, **P < 0.01, 24 h vs. 0 h). N.S.: no significance.

doi:10.1371/journal.pone.0049954.g001
with Hoechst 33258 and astrocytes were labeled with glial fibrillary acidic protein (GFAP), a marker specific to astrocytes, using immunofluorescence (purity > 98%, Fig. 1A). Purified astrocytes were treated with SKF83959 or vehicle for 2–60 min at concentrations ranging from 1–100 μM. ERK1/2 phosphorylation levels were measured by Western blot. As shown in Fig. 1B and 1C, SKF83959 induced a transient increase in ERK1/2 phosphorylation level in cultured astrocytes. Peak change was observed between 5 and 10 min after the application of SKF83959, and levels began to return to baseline at 30 min. A dose-dependent response curve showed that ERK1/2 phosphorylation became saturated at concentrations of 10, 30, and 50 μM SKF83959 and reached a maximum at 100 μM (Fig. 1D, 1E). For this reason, 10 min and 30 μM of SKF83959 incubation was selected for use in the following experiments. Because ERK1/2 affects astrocyte migration [18,24], we evaluated the effects of SKF83959 on astrocyte migration. After 24 h of incubation, SKF83959 (30 μM) was found to significantly enhance cell migration (Fig. 1F, 1G). This effect was markedly inhibited by pretreatment with PD90805 (20 μM, 30 min), a specific inhibitor of mitogen-activated protein kinase kinase (Fig. 1F, 1G).

**Astrocytic PI-linked D₁-like Receptors Mediate SKF83959-induced Increase in ERK1/2 Phosphorylation**

Putative PI-linked D₁-like receptors are the functional receptors for SKF83959. We next determined whether this receptor could mediate SKF83959-induced ERK1/2 phosphorylation. As expected, pretreatment of astrocytes with the selective antagonist of D₁-like receptor SCH23390 (10 μM, 30 min) prior to SKF83959 (30 μM) incubation prevented increases in ERK1/2 phosphorylation (Fig. 2A, 2B). SKF83959 has a high affinity to D₁-like receptor, but it also exhibits a weak or moderate affinity to other PLC-linked neurotransmitter receptors, such as D₂ receptor and α-adrenoceptor. The roles of other receptors in SKF83959-induced ERK1/2 phosphorylation were then tested. Pre-incubation with an antagonist of D₂ receptor spiperone (10 μM) (Fig. 2C, 2D) or an antagonist of α-adrenoceptor prazosin (1 μM) (Fig. 2E, 2F) did not exert inhibitory effects on SKF83959-induced ERK1/2 phosphorylation, suggesting that SKF83959-induced enhancement of ERK1/2 phosphorylation was mediated by neither the D₂ receptor nor the α-adrenoceptor. In general, these results indicate that selective activation of the putative PI-linked D₁-like receptors by SKF83959 is responsible for the increase in ERK1/2 phosphorylation.

---

**Figure 2. Involvement of putative PI-linked D₁-like receptors in SKF83959-induced ERK1/2 phosphorylation.** (A) Effects of D₁ dopamine receptor antagonist SCH23390 (10 μM, 30 min) on SKF83959 (30 μM, 10 min)-induced ERK1/2 phosphorylation. (B) Quantification of ERK1/2 phosphorylation level in astrocytes pre-incubated with SCH23390 and treated with SKF83959 (Mean ± S.E., n = 3, *P < 0.05, 10 min vs. 0 min). N.S.: no significance. (C) Effects of D₁ receptor antagonist spiperone (10 μM, 30 min) on SKF83959 (30 μM, 10 min)-induced ERK1/2 phosphorylation. (D) Quantification of ERK1/2 phosphorylation level in astrocytes pre-incubated with spiperone and treated with SKF83959 (Mean ± S.E., n = 3, **P < 0.01 or *P < 0.05, 10 min vs. 0 min). (E) Effects of α-adrenoceptor antagonist prazosin (1 μM, 30 min) on SKF83959 (30 μM, 10 min)-induced ERK1/2 phosphorylation. (F) Quantification of ERK1/2 phosphorylation level in astrocytes pre-incubated with prazosin and treated with SKF83959 (Mean ± S.E., n = 3, **P < 0.01 or *P < 0.05, 10 min vs. 0 min).

doi:10.1371/journal.pone.0049954.g002
SKF83959-induced Increase in ERK1/2 Phosphorylation is Dependent on PLC but not on IP3/Ca2+ Signaling

The results of our previous study showed that SKF83959-induced activation of D₁-like receptors increases intracellular Ca²⁺ level through mobilization of ER [15]. Because increases in internal Ca²⁺ can trigger ERK1/2 phosphorylation, we investigated whether an increase in internal Ca²⁺ could mediate SKF83959-induced ERK1/2 phosphorylation. Astrocytes were pretreated with a Ca²⁺ chelator BAPTA-AM (20 μM, 30 min), followed by application of SKF83959 (30 μM) for 10 min. BAPTA-AM failed to prevent the SKF83959-induced increase in ERK1/2 phosphorylation level, demonstrating that increases in intracellular Ca²⁺ are not necessary for the elevation in ERK1/2 phosphorylation level (Fig. 3A, 3B). Pretreatment with BAPTA-AM also failed to inhibit astrocyte migration, indicating that SKF83959 (24 h)-induced astrocyte migration is also not dependent on increases in internal Ca²⁺ (Fig. 3C, 3D). In addition, BAPTA-AM itself elevated the basal ERK1/2 phosphorylation level of cultured astrocytes.

Next, to confirm the specificity of BAPTA-AM as a Ca²⁺ chelator, we selected a well-known Ca²⁺/calmodulin binding protein CaMKII [25,26] as a positive control and evaluated SKF83959-induced CaMKII phosphorylation in the absence or presence of BAPTA-AM. As anticipated, SKF83959-induced enhancement of CaMKII phosphorylation was almost completely abolished by pretreatment with BAPTA-AM (20 μM, 30 min), suggesting that intracellular Ca²⁺ was indeed chelated by BAPTA-AM (Fig. 3E, 3F). To further confirm the contribution of intracellular Ca²⁺ on SKF83959-induced ERK1/2 phosphorylation increase, changes in ERK1/2 phosphorylation were assayed upon application of 2-APB, a blocker of ER IP3 receptors. As shown in Fig. 4A and 4B, 2-APB (100 μM) did not affect ERK1/2 phosphorylation level either. Surprisingly, we noted that 2-APB itself significantly reduced the basal ERK1/2 phosphorylation level of cultured astrocytes (Fig. 4A, 4B).

Because BAPTA-AM and 2-APB did not inhibit ERK1/2 phosphorylation induced by SKF83959, we assessed the effects of PLC, an upstream molecule of the mobilization of intracellular Ca²⁺, on SKF83959-induced ERK1/2 phosphorylation. U73122, a specific inhibitor of PLC, counteracted SKF83959's (30 μM, 10 min) ability to elevate the level of ERK1/2 phosphorylation (Fig. 4C, 4D). This indicates that other IP3-independent signaling pathways might contribute to SKF83959-induced ERK1/2 phosphorylation.

Figure 3. Contribution of intracellular Ca²⁺ to SKF83959-induced ERK1/2 phosphorylation. (A) Effects of BAPTA-AM (20 μM, 30 min) on SKF83959 (30 μM, 10 min)-induced ERK1/2 phosphorylation. (B) Quantification of ERK1/2 phosphorylation level in astrocytes pre-incubated with BAPTA-AM and treated with SKF83959 (Mean ± S.E., n = 3, *P < 0.05, 10 min vs. 0 min, **P < 0.01, BAPTA-AM 0 min vs. control 0 min). (C) Roles of BAPTA-AM (20 μM, 30 min) in SKF83959 (30 μM, 24 h)-induced migration of astrocytes. Bar: 5 μm. (D) Quantification of migration in astrocytes pre-incubated with BAPTA-AM and treated with SKF83959 (Mean ± S.E., n = 3, **P < 0.01, 24 h vs. 0 h). (E) Effects of BAPTA-AM (20 μM, 30 min) on SKF83959 (30 μM, 10 min)-induced CaMKII phosphorylation. (F) Quantification of CaMKII phosphorylation level in astrocytes pre-incubated with BAPTA-AM and treated with SKF83959 (Mean ± S.E., n = 3, *P < 0.05, 10 min vs. 0 min). N.S.: no significance.

doi:10.1371/journal.pone.0049954.g003
phosphorylation in our current system. A marked elevation in the basal level of ERK1/2 phosphorylation was observed after U73122 treatment in cultured astrocytes, like BAPTA-AM treatment (Fig. 4C, 4D).

PKCδ is Necessary for SKF83959-induced Increase in ERK1/2 Phosphorylation and Cell Migration in Cultured Rat Astrocytes

PKC is one of the molecules downstream of PLC activation. We determined whether SKF83959-induced ERK1/2 phosphorylation is involved in PKC activation. As shown in Fig. 5A and 5B, the non-selective PKC inhibitor GF109203X (10 μM) significantly
inhibited the increase in ERK1/2 phosphorylation level induced by SKF83959. To confirm the involvement of PKC in astrocytic ERK1/2 phosphorylation, astrocytes were incubated with PMA (5 μM), a specific activator of PKC. Our data show that PMA successfully enhanced ERK1/2 phosphorylation in cultured astrocytes, suggesting that PKC is indeed involved in SKF83959-induced ERK1/2 phosphorylation (Fig. 5C, 5D).

PKC exists in various isoforms with different characteristics. For example, activation of the typical PKCζ isoform is dependent on both Ca^{2+} and DAG, but activation of the novel PKCδ isoform is dependent on DAG but not on Ca^{2+}. We therefore investigated the roles of PKC isoforms in SKF83959-induced ERK1/2 phosphorylation using various pharmacological inhibitors. Rotterlin (5 μM), a specific inhibitor of PKCζ, significantly reduced the SKF83959-induced increase in ERK1/2 phosphorylation, and

the PKCζ inhibitor Go6976 (1 μM) did not (Fig. 6A, 6B, 6C, 6D). In line with the effect of rotterlin on SKF83959-induced ERK1/2 phosphorylation, rotterlin markedly attenuated SKF83959 (24 h incubation)-induced astrocyte migration (Fig. 6E, 6F). Pretreatment with Go6976 (1 μM, 30 min) had no effect on SKF83959-induced astrocyte migration (Fig. 6E, 6F). In conclusion, these data indicate that PKCζ functionally mediates the increase in ERK1/2 phosphorylation induced by SKF83959 in cultured rat astrocytes.

Discussion

The classical DA receptor subtypes are widely expressed in astrocytes [13,14]. However, the functional roles of the putative PI-linked D_{1}-like receptors in these cells are still not well understood. In the present study, we demonstrate that...
SKF83959 evokes a significant elevation in ERK1/2 phosphorylation in a time- and dose-dependent manner in cultured rat astrocytes. This elevation was transient and returned to the baseline within 60 min. However, one previous study demonstrated that it was CaMKII and CDK5, not ERK1/2, that was activated by SKF83959 [10]. The difference was probably due to the different samples used: SKF83959 was applied into cultured astrocytes in our current study, but the previous study was performed on brain slices [10]. SKF83959 is a specific agonist of the putative PI-linked D1-like receptors and SCH23390, D1-like receptor antagonist, was indeed found to prevent SKF83959-induced ERK1/2 phosphorylation elevation. The fact that the antagonists of D2 receptor and α-adrenoceptor both failed to inhibit ERK1/2 phosphorylation indicates that SKF83959-induced ERK1/2 phosphorylation involves putative PI-linked D1-like receptors.

ERK1/2 phosphorylation elevates ERK1/2 activity, which then promotes astrocyte migration [24]. Astrocytes are involved in various pathological conditions through membrane receptors such as the N-methyl-D-aspartic acid (NMDA) receptors and classical DA receptors [14,27]. Astrocytic putative PI-linked D1-like receptors were also reported to participate in internal Ca2+-mobilization and FGF-2 production in astrocytes [6]. Hence, we speculate that SKF83959 might influence astrocyte migration by regulating ERK1/2 phosphorylation. As shown in Fig. 1F and 1G, SKF83959 significantly promoted astrocyte migration, which could be largely inhibited by ERK1/2 inhibition. In this way, our results show that SKF83959 promoted ERK1/2 activation and the subsequent astrocyte migration, at least under in vitro conditions.

A number of studies have confirmed that the putative PI-linked D1-like receptors are Gq-related. Upon coupling to Gq protein, putative PI-linked D1-like receptors promoted IP3 production and the subsequent release of internal Ca2+ [28]. Although elevated levels of internal Ca2+ might mediate the activation of kinases such as CaMKII and ERK1/2 [10,29], BAPTA-AM-mediated chelation of intracellular Ca2+ did not inhibit SKF83959-induced ERK1/2 phosphorylation. However, as a positive control, the phosphorylation of classical Ca2+/camodulin-regulated kinase CaMKII was almost totally abolished by BAPTA-AM pretreatment [25,26]. In this way, these data indicate that the effects of SKF83959 on ERK1/2 activation are probably Ca2+-independent. This conclusion is further supported by the failure of 2-APB to inhibit SKF83959-induced ERK1/2 phosphorylation. However, other data are inconsistent with a Ca2+-independent scenario. BAPTA-AM itself markedly increased the basal level of ERK1/2 phosphorylation, and 2-APB reduced it, suggesting that Ca2+ might negatively regulate ERK1/2 activation. One previous study reported that calcineurin physically interacted with ERK1/2 and restrained its activity through de-phosphorylation [30]. Because Ca2+ generally binds to calcineurin, we postulated that BAPTA-AM itself might enhance ERK1/2 phosphorylation by eliminating negative Ca2+-calcineurin signals [31]. The compensatory Ca2+ entrance after 2-APB treatment might contribute to the ability of 2-APB to cause these reductions.

PLC is the pivotal molecule responsible for IP3 production [28]. We used a PLC inhibitor to investigate the role of PLC in SKF83959-induced ERK1/2 phosphorylation. Astrocytes exposed to the PLC inhibitor exhibited a significant reduction in the level of ERK1/2 phosphorylation, demonstrating that other PLC-associated signals might be involved in SKF83959-induced ERK1/2 phosphorylation. As with BAPTA-AM’s effect on ERK1/2 phosphorylation level, we observed an elevation in basal ERK1/2 phosphorylation level after treatment with U73122 alone. PLC activation causes increases in intracellular Ca2+ through two pathways, ER mobilization, and Ca2+ influx after attenuation of PIP2’s inhibition of membrane ligand-gated ion channels [32,33]. The reduction of Ca2+ influx after U73122 treatment might explain the increase in the basal level of ERK1/2 phosphorylation. Further investigations are required to evaluate the function of Ca2+–related signals in ERK1/2 activation in physiological conditions.

Diacylglycerol (DAG) is also present in the cytosol after PLC activation. DAG couples to PKC and positively regulates PKC activity in various disorders such as diabetes and cancer [34,35]. In our study, a non-selective PKC inhibitor effectively inhibited SKF83959-induced increases in ERK1/2 phosphorylation. Generally, PKC is divided into three sub-groups: conventional PKCs (ζ, β1, βII, and γ); novel PKCs (δ, ε, η, and θ); and atypical PKCs (ζ and λ) [36]. Distinct PKC isoforms take different characteristics [37]. For example, the conventional PKCs are Ca2+-dependent and activated by DAG, but novel PKCs are Ca2+-independent. The atypical PKCs are both Ca2+- and DAG-independent. To determine which specific isoform is involved in SKF83959-induced ERK1/2 phosphorylation, we investigated the effects of the different PKC isoforms on ERK1/2 phosphorylation. We found that PKCζ is not involved in ERK1/2 phosphorylation, but PKCδ inhibition robustly attenuated SKF83959-induced ERK1/2 phosphorylation and astrocyte migration. This is in accordance with the role of PKCδ in bradykinin-induced ERK1/2 phosphorylation and astrocyte migration [24]. It may provide us with a new target for the determination of the function of SKF83959.

In conclusion, our current data clearly suggest that the PLC-DAG-PKCδ signaling pathway mediates the SKF83959-induced ERK1/2 activation in cultured rat astrocytes. This might help us to understand the new pharmacological roles of SKF83959 in the nervous system (Fig. 7).

Acknowledgments

We warmly acknowledge the preliminary supporting from Professor Jianguo Chen and Dr. Qing Shu in Huazhong University of Science and Technology.

Author Contributions

Conceived and designed the experiments: CH WZ. Performed the experiments: CH. Analyzed the data: CH. Contributed reagents/materials/analysis tools: CH JW RL. Wrote the paper: CH.
SKF83959 Activates ERK1/2 via PKCδ in Rat Astrocytes

References

1. Misale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189–223.

2. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, et al. (2007) Novel insights in dopamine receptor physiology. Eur J Endocrinol 156 (Suppl 1): S13–S21.

3. Lin CW, Miller TR, Witte DG, Bianchi BR, Stashko M, et al. (1995) Characterization of cloned human dopamine D1 receptor-mediated calcium release in 293 cells. Mol Pharmacol 47: 131–139.

4. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, et al. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq11 in the striatum. Proc Natl Acad Sci 104: 654–659.

5. Jin LQ, Goswami S, Cai G, Zhen X, Friedman E (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 85: 376–386.

6. Zhang N, Zhou Z, Wang D, Li A, Yin Y, et al. (2009) Activation of phosphatidylinositol-linked D1 dopamine receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling. J Neurosci 29: 7766–7775.

7. Zhang H, Ma L, Wang F, Chen J, Zhen X (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson’s disease. Neuropharmacology 53: 125–133.

8. Zhen X, Goswami S, Friedman E (2005) The role of the phosphatidylinositol-linked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol Biochem Behav 88: 597–601.

9. Ma LQ, Liu C, Wang F, Xie N, Gu J, et al. (2009) Activation of phosphatidylinositol-linked novel D1 dopamine receptors inhibits high-voltage-activated Ca2+ currents in primary cultured striatal neurons. J Neurophysiol 101: 2230–2233.

10. Zhen X, Goswami S, Abdali SA, Gil M, Bakshi K, et al. (2004) Regulation of cyclin-dependent kinase 5 and calcium/calmodulin-dependent protein kinase II by phosphatidylinositol-linked dopamine receptor in rat brain. Mol Pharmacol 66: 1500–1507.

11. Giaime C, Koukalof A, Roux I, Holcman D, Rosuch N (2010) Astroglial networks: a step further in neutoglial and gliovascular interactions. Nat Rev Neurosci 11: 87–99.

12. Dauholt NC (2003) Glutamate uptake. Prog Neurobiol 65: 1–105.

13. Maspaggi V (2007) GABA and Neuroactive Steroid Interactions in Glia: New Roles for Old Players? Curr Neuropharmacol 5: 47–64.

14. Vermeulen RJ, Jongenelen CA, Langeveld CH, Wolters EC, Stoof JC, et al. (1994) Dopamine D1 receptor agonists display a distinct intrinsic activity in rat, monkey and human astrocytes. Eur J Pharmacol 269: 121–125.

15. Liu J, Wang F, Huang C, Long LH, Wu WN, et al. (2009) Activation of phosphatidylinositol-linked novel D1 dopamine receptor contributes to the calcium mobilization in cultured rat prefrontal cortical astrocytes. Cell Mol Neurobiol 29: 317–328.

16. Sharma GD, He J, Bazan HE (2003) p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J Biol Chem 278: 21989–21997.

17. Mu H, Wang X, Wang H, Lin P, Yao Q, et al. (2009) Lactosylceramide promotes cell migration and proliferation through activation of ERK1/2 in human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 297: H490–H498.

18. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM (2010) Transforming growth factor-β1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-κB pathways. J Neuroinflammation 7: 88.

19. Colucci-D’Amato L, Perrone-Capano C, di Porzio U (2003) Chronic activation of ERKs and neuroprotective effects. Biochem Pharmacol 25: 1053–1093.

20. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, et al. (1999) Activation of neuronal ERK in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10: 2411–2415.

21. Jacobsen KN, MacDonald H, Lemoine S, Dagle M, Grimes DA, et al. (2008) A Nurr1 point mutant, implicated in Parkinson’s disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription. Neurobiol Dis 29: 117–122.

22. Huang G, Hu ZL, Wu WN, Yu DF, Xiong QJ, et al. (2010) Existence and distinction of acid-evoked currents in rat astrocytes. Glia 58: 1415–1424.

23. Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19: 1–10.

24. Hsieh HL, Wu CY, Yang CM (2008) Bradykinin induces matrix metalloproteinase-9 expression and cell migration through a PKC-dependent ERK/Erk-1 pathway in astrocytes. Glia 56: 619–632.

25. Shifman JM, Choi MH, Mihalas S, Mayo SL, Kennedy MB (2006) Ca2+/calmodulin-dependent protein kinase II (CaMKII) is activated by calmodulin with two bound calcium. Proc Natl Acad Sci U S A 103: 13968–13973.

26. Pekpe S, Kinzer-Ursem T, Mihalas S, Kennedy MB (2010) A dynamic model of interactions of Ca2+, calmodulin, and catalytic subunits of Ca2+/calmodulin-dependent protein kinase II. PLoS Comput Biol 6: e1000675.

27. Krebs C, Fernandes HB, Sheldon C, Raymond LA, Baimbridge KG (2003) Functional NMDA receptor subtype 2B is expressed in astrocytes after ischemia in vivo and anoxia in vitro. J Neurosci 23: 3364–3372.

28. Domier TL, Zima AV, Maxwell JT, Hume S, Mignery GA, et al. (2006) IP3 receptor-dependent Ca2+ release modulates excitation-contraction coupling in rabbit ventricular myocytes. Am J Physiol Heart Circ Physiol 294: H596–H604.

29. Xiao Z, Wang T, Qin H, Huang C, Feng Y, et al. (2011) Endoplasmic reticulum Ca2+ release modulates endothelial nitric-oxide synthase via extracellular signal-regulated kinase (ERK): 1/2-mediated serine 635 phosphorylation. J Biol Chem 286: 20100–20108.

30. Ikeda Y, Miura T, Sakamoto J, Miki T, Tanno M, et al. (2006) Activation of ERK and suppression of calcineurin are intersecting mechanisms of cardioprotection afforded by delta-opioid receptor activation. Basic Res Cardiol 101: 418–426.

31. Fedke S, Okamura H, Hogun PG, Rao A (2003) Ca2+/calmodulin signalling in cells of the immune system. Biochem Biophys Res Commun 311: 1117–1132.

32. Gauster N, Shapiro MS (2007) Target-specific PIP2 signalling: how might it work? J Physiol 582: 967–975.

33. Lukacs V, Thyagarajan B, Varnai P, Balla A, Balla T, et al. (2007) Dual functions of GRK2: regulation of PKC and calcium signal in M1 receptor channel assays. J Biol Chem 282: 2230–2236.

34. Hiramatsu Y, Sekiguchi N, Hayashi M, Isshiki K, Yokota T, et al. (2002) Functional NMDA receptor subtype 2B is expressed in astrocytes after ischemia in vivo and anoxia in vitro. J Neurosci 23: 3364–3372.

35. Parker PJ, Murray-Rust J (2004) PKC at a glance. J Cell Sci 117: 131–132.

36. Parker PJ, Murray-Rust J (2004) PKC at a glance. J Cell Sci 117: 131–132.

37. Kheifets V, Mochly-Rosen D (2007) Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. Pharmacol Res 55: 467–476.